Physician profile
Jason Rivera
NPI 1114560950
$2,674.28
in general payments reported to CMS, 2019-2025
28 companies · $1,242 in 2025
The $1,242 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $222 · 2024: $1,211 · 2025: $1,242.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,654 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,654.06 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $457.23 | 2024-2025 | Korlym |
| Lilly USA, LLC | $310.55 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $299.30 | 2024-2025 | Airsupra, Breztri, Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $293.42 | 2024-2025 | |
| Glaxosmithkline, LLC. | $149.34 | 2024-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Abbvie INC. | $131.51 | 2024-2025 | |
| Amgen INC. | $123.05 | 2024-2025 | Repatha, Repatha |
| Novo Nordisk INC | $102.38 | 2023-2025 | Ozempic, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $101.82 | 2024 | Caplyta |
| Verona Pharma, INC. | $97.60 | 2025 | Ohtuvayre |
| Axsome Therapeutics, INC. | $77.77 | 2024-2025 | Auvelity |
| Phathom Pharmaceuticals, INC. | $75.15 | 2024-2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $67.88 | 2023-2025 | Quviviq, Quviviq |
| Merck Sharp & Dohme LLC | $60.70 | 2023-2025 | Verquvo, Capvaxive |
| Sumitomo Pharma America, INC. | $42.86 | 2024-2025 | Gemtesa |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.20 | 2024 | Xifaxan |
| Lundbeck LLC | $27.81 | 2024 | Rexulti |
| Alkermes, INC. | $25.96 | 2025 | Lybalvi |
| Baxter Healthcare | $25.76 | 2023 | Hillrom - Vest System Model 105 Home Care |
| Phadia US INC. | $25.23 | 2024 | Immunocap |
| Lexicon Pharmaceuticals, INC. | $25.06 | 2023 | Inpefa |
| Otsuka America Pharmaceutical, INC. | $22.30 | 2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.53 | 2025 | Jardiance |
| Esperion Therapeutics, INC. | $19.71 | 2023 | Nexletol |
| Exact Sciences Corporation | $18.40 | 2025 | The Cologuard Plus Collection Kit |
| Pfizer INC. | $15.44 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $13.86 | 2025 | Zoryve |
| Cequr Corporation | $13.46 | 2025 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Rivera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.